Business Context and Reporting Period
Oragenics, Inc. filed a Form 8-K on June 12, 2008, reporting the closing of a private placement financing. The company is incorporated in Florida and operates from Gainesville, Florida.
Key Financial Metrics
- Cash Raised: $2,600,000 in additional capital received upon closing.
- Equity Issued: 5,777,778 shares of common stock.
- Warrants Issued: Warrants to acquire 5,777,778 shares of common stock.
- Warrant Exercise Price: $1.30 per share, exercisable immediately.
- Investor Profile: Purchasers were accredited investors and existing shareholders.
Material Changes
The filing reports a material definitive agreement entered into on June 12, 2008. This transaction represents a significant increase in the company's capital base and an expansion of its outstanding share count through the issuance of new common stock and warrants. The filing does not provide comparative financial data or prior period metrics.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard legal disclosures associated with the securities offering. The transaction was consummated pursuant to an exemption under Section 4(2) of the Securities Act of 1933. Purchasers were granted piggyback registration rights for future registration statements.
Investor Verification Checklist
- Verify the exact number of shares issued (5,777,778) and the total capital raised ($2,600,000) against the company's latest 10-Q or 10-K to assess dilution impact.
- Review Exhibit 10.1 (Securities Purchase Agreement) for specific covenants or restrictions imposed by the new investors.
- Confirm the exercise terms and expiration date of the warrants issued at $1.30 per share.
- Check subsequent filings for the registration statement mentioned regarding piggyback rights.